Literature DB >> 21312398

Treatment implications of the schizophrenia prodrome.

Tejal Kaur1, Kristin S Cadenhead.   

Abstract

Schizophrenia is a debilitating neurodevelopmental disorder that strikes at a critical period of a young person's life. Early identification of individuals in the prodromal phase of a psychotic illness can lead to earlier treatment and perhaps prevention of many of the devastating effects of a first psychotic episode. International research efforts have demonstrated the success of community outreach and education regarding the schizophrenia prodrome and it is now possible to use empirically defined clinical and demographic criteria to identify individuals at a substantially increased risk for a psychotic illness. The development of clinical staging criteria for psychosis that incorporates type and severity of clinical symptoms, level of global and social functioning, family history, substance use, neurocognitive functioning, and perhaps neurobiological information, could help to specify appropriate treatment for vulnerable individuals at different phases of the prodrome. Preliminary psychosocial and pharmacologic treatment studies report initial success in reducing severity of prodromal symptoms in "at-risk" samples, but further work is needed to refine the prodromal criteria and perform well controlled treatment studies in adequately powered samples. Treatment algorithms can then be tailored to presenting symptoms, number of risk factors present, and evidence of progression of the illness, to assure appropriate, safe and effective interventions in the early stages of psychosis.

Entities:  

Mesh:

Year:  2010        PMID: 21312398      PMCID: PMC3136161          DOI: 10.1007/7854_2010_56

Source DB:  PubMed          Journal:  Curr Top Behav Neurosci        ISSN: 1866-3370


  98 in total

Review 1.  Serotonin and dopamine interactions in psychosis prevention.

Authors:  Neil M Richtand; Robert K McNamara
Journal:  Prog Brain Res       Date:  2008       Impact factor: 2.453

2.  Evidence-based health policy--lessons from the Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

3.  One hundred years of schizophrenia: a meta-analysis of the outcome literature.

Authors:  J D Hegarty; R J Baldessarini; M Tohen; C Waternaux; G Oepen
Journal:  Am J Psychiatry       Date:  1994-10       Impact factor: 18.112

Review 4.  The prodromal phase of first-episode psychosis: past and current conceptualizations.

Authors:  A R Yung; P D McGorry
Journal:  Schizophr Bull       Date:  1996       Impact factor: 9.306

Review 5.  Early detection and intervention of psychosis. A review.

Authors:  Raimo K R Salokangas; Thomas H McGlashan
Journal:  Nord J Psychiatry       Date:  2008       Impact factor: 2.202

Review 6.  From genes to psychoses and back: the role of the 5HT2alpha-receptor and prepulse inhibition in schizophrenia.

Authors:  Wolfgang Maier; Rainald Mössner; Boris B Quednow; Michael Wagner; René Hurlemann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

7.  Randomised-control trial of family intervention for 78 first-episode male schizophrenic patients. An 18-month study in Suzhou, Jiangsu.

Authors:  M Zhang; M Wang; J Li; M R Phillips
Journal:  Br J Psychiatry Suppl       Date:  1994-08

8.  Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals.

Authors:  Daqiang Sun; Lisa Phillips; Dennis Velakoulis; Alison Yung; Patrick D McGorry; Stephen J Wood; Theo G M van Erp; Paul M Thompson; Arthur W Toga; Tyrone D Cannon; Christos Pantelis
Journal:  Schizophr Res       Date:  2009-01-12       Impact factor: 4.939

9.  First onset and early symptomatology of schizophrenia. A chapter of epidemiological and neurobiological research into age and sex differences.

Authors:  H Häfner; A Riecher-Rössler; K Maurer; B Fätkenheuer; W Löffler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

10.  Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America.

Authors:  Tyrone D Cannon; Kristin Cadenhead; Barbara Cornblatt; Scott W Woods; Jean Addington; Elaine Walker; Larry J Seidman; Diana Perkins; Ming Tsuang; Thomas McGlashan; Robert Heinssen
Journal:  Arch Gen Psychiatry       Date:  2008-01
View more
  9 in total

1.  Staged Treatment in Early Psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients.

Authors:  Barnaby Nelson; G Paul Amminger; Hok Pan Yuen; Nicky Wallis; Melissa J Kerr; Lisa Dixon; Cameron Carter; Rachel Loewy; Tara A Niendam; Martha Shumway; Sarah Morris; Julie Blasioli; Patrick D McGorry
Journal:  Early Interv Psychiatry       Date:  2017-07-18       Impact factor: 2.732

2.  Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.

Authors:  Masakuni Horiguchi; Kayleen E Hannaway; Adesewa E Adelekun; Karu Jayathilake; Herbert Y Meltzer
Journal:  Neuropsychopharmacology       Date:  2012-06-27       Impact factor: 7.853

Review 3.  Update on the development of lurasidone as a treatment for patients with acute schizophrenia.

Authors:  Norio Yasui-Furukori
Journal:  Drug Des Devel Ther       Date:  2012-05-08       Impact factor: 4.162

4.  INCREASED INTERNET USE AND POORER ABILITY TO MANAGE EMOTIONS IN YOUTH AT HIGH-RISK FOR PSYCHOSIS.

Authors:  Andrea Pelletier-Baldelli; Lindsay Ives; Vijay A Mittal
Journal:  Schizophr Res Cogn       Date:  2015-12-01

5.  Understanding the schizophrenia prodrome.

Authors:  Manju George; Shreemit Maheshwari; Suhas Chandran; J Shivananda Manohar; T S Sathyanarayana Rao
Journal:  Indian J Psychiatry       Date:  2017 Oct-Dec       Impact factor: 1.759

6.  Treatment-Resistant to Antipsychotics: A Resistance to Everything? Psychotherapy in Treatment-Resistant Schizophrenia and Nonaffective Psychosis: A 25-Year Systematic Review and Exploratory Meta-Analysis.

Authors:  Daniela Polese; Michele Fornaro; Mario Palermo; Vincenzo De Luca; Andrea de Bartolomeis
Journal:  Front Psychiatry       Date:  2019-04-17       Impact factor: 4.157

Review 7.  Potential use of clinical polygenic risk scores in psychiatry - ethical implications and communicating high polygenic risk.

Authors:  A C Palk; S Dalvie; J de Vries; A R Martin; D J Stein
Journal:  Philos Ethics Humanit Med       Date:  2019-02-27       Impact factor: 2.464

8.  Polygenic risk scores across the extended psychosis spectrum.

Authors:  Lukasz Smigielski; Sergi Papiol; Peter Falkai; Thomas G Schulze; Edna Grünblatt; Anastasia Theodoridou; Karsten Heekeren; Miriam Gerstenberg; Diana Wotruba; Roman Buechler; Per Hoffmann; Stefan Herms; Kristina Adorjan; Heike Anderson-Schmidt; Monika Budde; Ashley L Comes; Katrin Gade; Maria Heilbronner; Urs Heilbronner; Janos L Kalman; Farahnaz Klöhn-Saghatolislam; Daniela Reich-Erkelenz; Sabrina K Schaupp; Eva C Schulte; Fanny Senner; Ion-George Anghelescu; Volker Arolt; Bernhard T Baune; Udo Dannlowski; Detlef E Dietrich; Andreas J Fallgatter; Christian Figge; Markus Jäger; Georg Juckel; Carsten Konrad; Vanessa Nieratschker; Jens Reimer; Eva Reininghaus; Max Schmauß; Carsten Spitzer; Martin von Hagen; Jens Wiltfang; Jörg Zimmermann; Anna Gryaznova; Laura Flatau-Nagel; Markus Reitt; Milena Meyers; Barbara Emons; Ida Sybille Haußleiter; Fabian U Lang; Thomas Becker; Moritz E Wigand; Stephanie H Witt; Franziska Degenhardt; Andreas J Forstner; Marcella Rietschel; Markus M Nöthen; Till F M Andlauer; Wulf Rössler; Susanne Walitza
Journal:  Transl Psychiatry       Date:  2021-11-26       Impact factor: 6.222

9.  Antipsychotic Treatment Reduces Indices of Oxidative Stress in First-Episode Psychosis Patients.

Authors:  Kärt Kriisa; Liina Haring; Eero Vasar; Kati Koido; Sven Janno; Veiko Vasar; Kersti Zilmer; Mihkel Zilmer
Journal:  Oxid Med Cell Longev       Date:  2016-07-27       Impact factor: 6.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.